Biodronate 30 mg Injection

About Biodronate 30 mg Injection:

Biodronate 30 mg Injection is a bone resorption inhibitor that alters bone formation and breakdown in the body. This process can slow bone loss and may help prevent bone fractures.

Biodronate 30 mg Injection is indicated for the treatment of hypercalcemia of malignancy, Paget’s disease of bone, and osteolytic bone lesions associated with breast cancer and multiple myeloma.

Each vial contains Disodium Pamidronate equivalent to anhydrous Disodium Pamidronate 30mg, Mannitol 470 mg.

For reconstitution 10 ml sterile water for injections.

Pamidronate is a bisphosphate class of medications, that works by inhibiting bone resorption and decreasing mineralization. Pamidronate reduces the elevation of osteoclast precursors (cells that break down bone) onto the bone, therefore, slows down bone loss, allowing the bone-building cells (osteoblasts) to work more effectively.

Use of Biodronate 30 mg Injection:

• Biodronate 30 mg Injection is prescribed for the treatment of moderate or severe hypercalcemia associated with malignancy and Paget’s disease of bone (a disorder of the bone remodeling process in which the body absorbs old bone and forms abnormal new bone, which is fragile).
• It can also be prescribed to treat osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer or multiple myeloma.

Usage direction of Biodronate 30 mg Injection:

• Biodronate 30 mg Injection is intended for Intravenous Infusion only.
• Before administration further dilution is required.
• Lyophilized Biodronate 30 mg Injection needs to be reconstituted with 10 ml of sterile water, which is provided with this pack.
• The Physician will advise the right dose & direction of administration as per the patient’s condition.
• Read enclosed leaflet or label instruction before administration.
• Self-administration is strictly prohibited.

Precaution & Related information of Biodronate 30 mg Injection:

• If hypersensitive or allergic to any of the ingredients of Biodronate 30 mg Injection, consult with the physician.
• If patient has been associated with renal toxicity manifested as deterioration of renal function and potential renal failure.
• If patients with a history of thyroid surgery may have relative hypoparathyroidism, which may predispose to hypocalcemia with Biodronate 30 mg Injection.
• If patients receive Biodronate 30 mg Injection for bone metastases.
• Osteonecrosis of the jaw (ONJ) has been reported predominantly in cancer patients treated with intravenous bisphosphonates, including Biodronate 30 mg Injection.
• History of dental disease.
• Store the reconstituted solution in a refrigerator (2°C to 8°C), do not freeze.
• Biodronate 30 mg Injection should be used within 24 hours.
• The Injection should not be used if contains visible particulate matter after reconstitution.
• Concomitant administration of this one with other medicine is prohibited.
• Consult with the physician during pregnancy and lactation.
• Keep out of reach of children.

Storage condition of Biodronate 30 mg Injection:

• Store at controlled room temperature not exceeding 30°C.